NCT03273322View on ClinicalTrials.gov

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 13, 2017

Primary Completion Date

November 20, 2018

Study Completion Date

September 30, 2019

Conditions
Atrial FibrillationAtrial AppendageHemorrhage
Interventions
DRUG

Rivaroxaban 10 mg qd

10mg qd

DRUG

Rivaroxaban 15 mg qd

15mg qd

DRUG

DAPT

Aspirin 75 mg qd + Clopidogrel 75 mg qd

Trial Locations (1)

75013

Institut de Cardiologie - Hôpital Pitié-Salpêtrière, Paris

Sponsors
All Listed Sponsors
collaborator

Action Research Group

OTHER

collaborator

Bayer

INDUSTRY

lead

Assistance Publique - Hôpitaux de Paris

OTHER